What public companies just told the SEC about AI, read straight from the filings. Every quote links the original document.
AMC Names AI Filmmaking an Audience-Acceptance Risk
In an 8-K filed September 21, AMC Entertainment Holdings listed AI-generated content alongside labor stoppages and tariff burdens in its forward-looking risk disclosures. The specific language:
the use of artificial intelligence ("AI") technology in the filmmaking process and audience acceptance of movies made utilizing AI technology
AMC does not produce films; it exhibits them. The same filing separately names its "lack of control over distributors of films" as a risk. Read together, the disclosure treats AI adoption by studios as an upstream variable that could alter what reaches theaters and whether audiences buy tickets.
AI Power Demand Is Pulling Non-Tech Companies Into Energy
Algorhythm Holdings (RIME) announced on September 21 that it is acquiring Azure Energy, a renewable biomass power generation company founded in 2025. The deal is structured through a new class of preferred stock and requires shareholder approval. The rationale given:
The acquisition represents a transformational strategic transaction for the Company, establishing the Company in the rapidly expanding U.S. power infrastructure market as artificial intelligence, hyperscale computing and advanced manufacturing drive substantial new demand for reliable power generation.
Also on September 21, Solidion Technology (STI) filed an 8-K on a board appointment. The company description in the release identifies "UPS systems serving the artificial intelligence (AI) data center market" among its battery production targets. Solidion makes battery materials including silicon anodes and lithium-sulfur components, and holds over 385 patents.
Drug Discovery Filings Start Defining AI Competition in Legal Terms
Iambic Therapeutics included a stockholder agreement in its S-1 that defines a "Competitor" around AI capabilities rather than therapeutic area. The definition covers any person engaged in "using artificial intelligence for (i) molecular and/or material design and/or (ii) drug discovery," with a carve-out for financial investors holding under 10% who hold no board rights. Biotech non-compete language is typically structured around disease indications, not the underlying technology.
Passage BIO included AI risk language in an S-4 merger filing, stating that "Issues relating to our use of artificial intelligence ('AI') in the discovery and development of our product candidates could adversely affect our business and operating results." The company confirms it incorporates AI into its platform technologies and names the risk that AI-generated analyses could be deficient.
Agentic AI Moves From Marketing Copy Into S-1 Filings
SB Energy, a data center developer filing an S-1 amendment, makes a direct scale argument built on agentic AI inference demand:
The frontier AI models of the next decade, and the inference demand emerging from agentic AI and broader enterprise adoption, may not be able to be trained or served from sub-scale facilities. Our customers demand mega-sites, and we are among the few data center providers positioned to deliver them.
Oura named agentic AI as an external partnership in its S-1 amendment: the smart ring company lists Lumeris and its "Agentic AI Tom platform" among its connected care pathways, alongside Essence Healthcare and Maven Clinic. That positions Oura as infrastructure for third-party agentic systems rather than an agentic AI company itself.
MindWalk Holdings (HYFT) described itself in a 6-K as "a Bio-Native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require, integrating AI, data, and advanced wet lab capabilities into one connected discovery ecosystem." The announcement covers AMD Inference Microservices availability for its OpenFold3 protein structure platform through the Vultr Kubernetes Engine Marketplace.